Downregulation of class II molecules on epidermal Langerhans cells in Lyme borreliosis

Br J Dermatol. 2000 Oct;143(4):786-94. doi: 10.1046/j.1365-2133.2000.03776.x.

Abstract

Background: Borrelia burgdorferi can be isolated from the skin of patients with acrodermatitis chronica atrophicans (ACA), a late-stage manifestation of Lyme borreliosis; despite a marked T-cell infiltrate in lesional skin and high antibody titres in patients' sera.

Objectives: To determine whether antigen-presenting Langerhans cells (LCs), which reportedly show signs of injury in erythema chronicum migrans (ECM), the early stage of disease, are altered in ACA.

Patients/methods: We studied the immunophenotype of cutaneous leucocytes on cryostat sections of lesional skin from both ECM and ACA patients.

Results: The total number of CD1a+ cells evaluated by semiautomatic image analysis was lower in ECM (594 +/- 263 cells mm(-2) epidermis) than in ACA (835 +/- 317 cells mm(-2) epidermis). HLA-DR expression was remarkably downregulated on CD1a+ LCs to 29% in ECM and 18% in ACA, whereas in normal skin, most of the epidermal CD1a+ dendritic cells were HLA-DR+. The inflammatory infiltrate was mainly composed of CD68+ macrophages and CD45RO+ memory T cells, with a predominance of CD4+ helper T cells.

Conclusions: It is conceivable that the downregulation of major histocompatibility complex class II molecules on LC in both the early and late skin manifestations of Lyme borreliosis is indicative of a poorly effective anti-B. burgdorferi immune response and thus at least partly responsible for the insufficient elimination of this micro-organism from ACA skin.

MeSH terms

  • Acrodermatitis / immunology
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD1 / metabolism
  • Chronic Disease
  • Down-Regulation*
  • Epidermis / immunology*
  • Female
  • Fluorescent Antibody Technique
  • HLA-DR Antigens / metabolism*
  • Humans
  • Immunoenzyme Techniques
  • Immunophenotyping
  • Langerhans Cells / immunology*
  • Lyme Disease / immunology*
  • Male
  • Middle Aged

Substances

  • Antigens, CD1
  • HLA-DR Antigens